Geron Corporation
Geron is the Californian company behind imetelstat, the first telomerase inhibitor to reach approval, cleared by the FDA in 2024 for lower-risk myelodysplastic syndromes with transfusion-dependent anaemia.
Overview
Geron Corporation, based in Foster City, California, spent three decades on telomerase biology before its oligonucleotide telomerase inhibitor imetelstat (Rytelo) was approved by the FDA in June 2024 for adults with lower-risk myelodysplastic syndromes and transfusion-dependent anaemia who had failed or were ineligible for erythropoiesis-stimulating agents, on the IMerge trial. Imetelstat is also in a phase 3 trial in relapsed or refractory myelofibrosis. Company facts are from the official website and FDA approval records.
Scorecard
All companies- approved products +6
- modalities +2
- regions +2
- registry trials +10
Similar pages
not linked directly; found by shared links- Companymedac
Shares Myelodysplastic syndromes / neoplasms (MDS) and the tag fda-oce-applicant.
- CompanyGamida Cell
Shares Myelodysplastic syndromes / neoplasms (MDS) and the tag fda-oce-applicant.
- CompanyRyvu Therapeutics
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Myelodysplastic syndromes / neoplasms (MDS).
- TermAnaemia
Shares Imetelstat, Myelodysplastic syndromes / neoplasms (MDS).
- JournalLeukemia research
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Myelodysplastic syndromes / neoplasms (MDS).
- Key paperIMerge: imetelstat, a telomerase inhibitor, for transfusion-dependent lower-risk MDS after erythropoietin has failed
Shares Imetelstat, Myelodysplastic syndromes / neoplasms (MDS).
- Key paperCOMMANDS: luspatercept versus epoetin alfa as first treatment for anaemia in lower-risk MDS needing transfusions
Shares Imetelstat, Myelodysplastic syndromes / neoplasms (MDS).
- TechnologyTransfusion support and anaemia management
Shares Imetelstat, Myeloproliferative neoplasms (PV, ET, myelofibrosis), Myelodysplastic syndromes / neoplasms (MDS).